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Background: This exploratory study evaluated the safety/efficacy of nintedanib or sunitinib as first-line therapy in patients with
advanced renal cell carcinoma (RCC).
Methods: Ninety-six patients were randomised (2:1) to either nintedanib (200mg twice daily) or sunitinib (50mgkg 1 once daily (4
weeks on treatment; 2 weeks off)). Primary endpoint was progression-free survival (PFS) at 9 months. P-values reported are
descriptive only; the study was not powered for such comparisons.
Results: Progression-free survival at 9 months was comparable between nintedanib and sunitinib (43.1% vs 45.2%, respectively;
P¼ 0.85). Median PFS was 8.4 months in each group (hazard ratio (HR), 1.12; 95% confidence interval (CI): 0.70–1.80; P¼ 0.64).
Median overall survival was 20.4 and 21.2 months for nintedanib and sunitinib, respectively (HR, 0.92; 95% CI: 0.54–1.56; P¼ 0.76).
Overall incidence of any grade adverse events (AEs) was comparable (90.6% vs 93.8%); AEs gradeX3 were lower with nintedanib
than sunitinib (48.4% vs 59.4%). Nintedanib was associated with lower incidences of some AEs typical of antiangiogenic tyrosine
kinase inhibitors (TKIs): hypertension, hypothyroidism, hand–foot syndrome, cardiac disorders and haematological abnormalities.
Conclusions: In patients with advanced RCC, nintedanib has promising efficacy and similar tolerability to sunitinib, and a
manageable safety profile with fewer TKI-associated AEs.
Over the past decade, antiangiogenic agents have become established
as effective treatment options for patients with advanced renal cell
carcinoma (RCC) (Conti et al, 2013). The currently approved
tyrosine kinase inhibitors (TKIs), including sunitinib, sorafenib,
pazopanib and axitinib, block tumour angiogenesis through
inhibition of proangiogenic signalling receptors, such as vascular
endothelial growth factor receptors (VEGFRs) and platelet-derived
growth factor receptor-a (PDGFR-a; Bukowski, 2012; Conti et al,
2013). Sunitinib is one of the current standard-of-care options for
treatment-naive patients with metastatic RCC, targeting VEGFR-1-3
and PDGFR-a/b (Pfizer Ltd, 2014).
Despite the efficacy of TKIs in patients with advanced RCC,
disease progression occurs within a median of 9–12 months after
treatment initiation (Hutson et al, 2008; Motzer et al, 2009;
Sternberg et al, 2010). Prolonged treatment with some TKIs has
also been associated with significant adverse events (AEs),
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including QT prolongation, cardiac toxicity and hypertension
(Di Lorenzo et al, 2011; Ravaud, 2011; Ghatalia et al, 2015). In the
pivotal Phase III study of sunitinib in RCC, 19% of patients
discontinued sunitinib due to AEs (Motzer et al, 2009). Evidence
demonstrates that sunitinib dose reductions or discontinuations
are correlated with shorter survival for patients with advanced
RCC (Porta et al, 2014). New therapies that provide a survival
benefit with a manageable safety profile are needed.
Nintedanib is an orally available triple angiokinase inhibitor that
specifically inhibits VEGFR-1-3, PDGFR-a/b and fibroblast growth
factor receptor (FGFR)-1-3, as well as FLT-3, RET and members of
the Src family (Hilberg et al, 2008; Reck et al, 2014). Unlike other
currently approved antiangiogenic therapies that inhibit signalling
through VEGFR and/or PDGFR, nintedanib simultaneously inhibits
three angiogenic signalling pathways. A growing body of evidence
suggests an important role for FGFR signalling in acquired
resistance to VEGFR inhibition (Casanovas et al, 2005). Further-
more, the role of both FGF and PDGF signalling in the development
of anti-VEGF resistance is supported by the clinical observation that
FGF and PDGF plasma levels increase prior to disease progression
in patients receiving anti-VEGF therapy (Kopetz et al, 2010).
Nintedanib (200mg twice daily (bid)) in combination with
chemotherapy has demonstrated significant efficacy in two Phase
III studies of advanced non-small cell lung cancer (NSCLC; Hanna
et al, 2013; Reck et al, 2014) and a Phase III study of advanced
ovarian cancer (Du Bois et al, 2013). Recent Phase II studies
comparing nintedanib and sorafenib as first-line monotherapy in
patients with hepatocellular carcinoma (HCC) showed similar
efficacy between the treatments in both Asian and European
patient populations (Cheng et al, 2015; Palmer et al, 2015) with a
more favourable safety profile reported for nintedanib in Asian
patients (Cheng et al, 2015). Nintedanib has also shown significant
efficacy in two Phase III trials of patients with idiopathic
pulmonary fibrosis (IPF), a progressive and severely debilitating
lung disease (Richeldi et al, 2014). Nintedanib is currently
approved in the European Union (EU) in combination with
docetaxel for locally advanced, metastatic or locally recurrent
NSCLC of adenocarcinoma histology after failure of first-line
chemotherapy (Boehringer Ingelheim, 2014b). Nintedanib is also
approved in the EU and the US as monotherapy for patients with
IPF (Boehringer Ingelheim, 2014a).
Clinical experience with nintedanib monotherapy in RCC has
been reported from a Phase I study of patients with various solid
tumour types, including metastatic RCC (Mross et al, 2010). Of the
10 patients with advanced RCC in that study, one patient had a
partial response to treatment and one patient with lung metastases
had a complete response (Mross et al, 2010). Two patients with
advanced RCC received nintedanib treatment for 41 year, and
seven were treated for at least 5 months. Nintedanib demonstrated
a generally manageable safety profile, with the most frequently
observed AEs being gastrointestinal effects (i.e., nausea, vomiting
and diarrhoea; Mross et al, 2010).
Following the promising Phase I data, the current Phase II study
(ClinicalTrials.gov, NCT01024920; Study 1199.26) evaluated the
safety and efficacy of nintedanib as first-line therapy for previously
untreated patients with advanced RCC. The study design included
co-primary safety and efficacy objectives. The co-primary safety
data for the nintedanib group have been reported previously
(Eisen et al, 2013) and here we report on the co-primary efficacy
and additional efficacy and safety endpoints.
PATIENTS AND METHODS
Patients. This study was conducted at 13 centres in five countries
(Hungary, Poland, Romania, UK and Ukraine). Adults (age X18
years) with a histologically confirmed diagnosis of unresectable or
metastatic RCC with clear cell component, and measurable disease
according to Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 were eligible for inclusion (Supplementary
Table S1; Eisenhauer et al, 2009; Eisen et al, 2013).
All patients provided written informed consent. The clinical
trial protocol was approved by the local and national independent
ethics committees for each trial centre. The study was conducted in
accordance with the International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) Harmonized Tripartite Guideline on Good
Clinical Research Practice (1997) and with the principles of the
Declaration of Helsinki.
Study design and treatments. This randomised, multicentre,
open-label, parallel-group Phase II study evaluated the safety and
efficacy of nintedanib. The primary objective was to investigate the
cardiac safety of nintedanib in terms of its effect on patients’ QT
interval, as reported previously (Eisen et al, 2013). The co-primary
objective was to compare the efficacy and safety of nintedanib vs
sunitinib ahead of potential Phase III clinical evaluation. However,
this comparison was exploratory, and the study was not powered to
allow a formal statistical comparison between the treatment arms.
Given the exploratory nature of the treatment comparison,
patients were randomised in a 2 : 1 ratio to receive either oral
nintedanib (200mg bid) continuously in 4-week cycles or oral
sunitinib (50mg kg 1) once daily in 6-week cycles (4 weeks of
sunitinib followed by 2 weeks without treatment). Randomisation
was performed using a telephone Interactive Voice/Web-based
Randomization System (IVRS/IWRS). Randomisation was strati-
fied according to each patient’s Memorial Sloan-Kettering Cancer
Center (MSKCC) risk score (favourable/intermediate vs poor)
(Motzer et al, 1999) and prior nephrectomy for RCC (yes vs no).
Patients were treated until disease progression (according to
RECIST version 1.1), death, unacceptable AEs, or withdrawal of
consent for any other reasons. Two dose-reduction levels were
available for patients experiencing drug-related AEs: 150 and
100mg bid for nintedanib and 37.5 and 25mg/kg once daily for
sunitinib. Dose reductions in the nintedanib group were indicated
for patients with diarrhoea grade 2 for 47 days despite optimal
management; vomiting grade X2; elevations in alanine amino-
transferase (ALT) or aspartate aminotransferase (AST) levels grade
X2 together with elevated bilirubin levels grade 41; or any other
AE grade 3/4. Dose reductions in the sunitinib group were
indicated for patients with any AE grade 3/4. Treatment was
discontinued if a third event occurred despite dose reductions.
Where appropriate, patients were permitted to receive full
supportive care, including transfusion of blood and blood
products, and treatment with antibiotics, antiemetics, antidiar-
rhoeal agents, analgesics, erythropoietin or bisphosphonates.
Additional chemo-, immuno-, radio- or hormone therapy was
not permitted during the trial (with the exception of hormone
replacement therapy). Palliative radiotherapy to control symptoms
was permitted although radiated target lesions were no longer to be
considered as target lesions.
Data in this report are for the analysis conducted 3 years after
randomisation of the final patient, with a cut-off date of 21 February
2014. The study was still ongoing at the time of the cut-off.
Endpoints and assessments. All efficacy parameters were assessed
by the study investigators, without central review. The primary
safety endpoint was change in QT interval from baseline to day 15
for nintedanib-treated patients (Eisen et al, 2013). The primary
efficacy endpoint was investigator-assessed progression-free survi-
val (PFS) at 9 months (defined as the proportion of patients
without objective tumour progression (RECIST version 1.1) and
alive 9 months after randomisation). Progression-free survival at 9
months was selected on the basis that the data available at the time
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that the study was designed suggested that the mean PFS for
patients receiving sunitinib was B9 months (Motzer et al, 2006).
Secondary efficacy endpoints included PFS, objective response
(OR), duration of OR, overall survival (OS), time to treatment
failure (TTF), time to progression (TTP) (Supplementary Table
S2), and the pharmacokinetic characteristics at day 15. Disease
assessments were performed based on tumour measurements
evaluated according to RECIST version 1.1 (computed tomography
or magnetic resonance imaging performed at baseline and every 12
weeks after treatment initiation), and graded by the investigator.
The incidence and severity of AEs (according to Common
Terminology Criteria for Adverse Events (CTCAE) version 3.0;
Cancer Therapy Evaluation Program (2006)), and the laboratory
parameters, vital signs, electrocardiogram (ECG) profiles and
physical examination results were also assessed.
Statistical analysis. The sample size in the nintedanib group was
selected to ensure sufficient power to assess the primary safety
endpoint. Using a paired t-test with a one-sided significance level
of 0.05, a sample size of 60 patients had 90% power to reject the
null hypothesis that the difference in QTcF means (post-
treatment–baseline) would be 410ms (i.e., above the regulatory
threshold) in favour of the alternative hypothesis that the two
means were equivalent, when the expected mean difference was
2.70ms with a SD of 19ms (Eisen et al, 2013). With 60 patients in
the nintedanib group, an additional 30 patients in the sunitinib
group provided a high probability of recording any numerically
positive treatment effect on the primary efficacy endpoint (i.e., a
greater proportion of patients with estimated 9-month PFS with
nintedanib versus sunitinib) of B70%, although this was not
derived from hypothesis testing. All analyses in this report were
descriptive and exploratory in nature, and performed on the
treated set (patients who received at least one dose of study
treatment). A post hoc analysis also compared outcomes in the
subpopulation of patients with bone or liver metastases at baseline,
due to recent data showing a negative impact of these metastatic
sites on survival in RCC for patients treated with targeted agents
(Mckay et al, 2014).
The primary efficacy endpoint of 9-month PFS was derived
from Kaplan–Meier (KM) estimates in order to take account of
patients who were censored before 9 months (e.g. due to missing
tumour assessments or switching to alternative therapy prior to
progression) and compared between treatments using a normal
approximation test. OR was assessed according to RECIST version
1.1. The number and percentage of responders was summarised
along with the duration of response; the objective response rate was
compared using a logistic regression model stratified by Motzer
risk score and previous surgery for RCC. Additional efficacy
endpoints of TTP, TTF and OS were evaluated using KM analysis;
OS was calculated as the time to death in days. All patients were
followed up for survival until death due to any cause, withdrawal of
consent or 3 years following enrolment of the final subject.
Progression-free survival and OS were analysed using a stratified
log-rank test while HRs and CIs for PFS, TTP, TTF and OS were
obtained from stratified Cox proportional hazards models; in both
cases, the stratification factors were Motzer risk score and previous
surgery for RCC. Post hoc analyses in the subpopulation of patients
with bone or liver metastases were unstratified. Post hoc analyses of
patient demographic and baseline characteristics, AEs reported in
X10% of patients and AEs associated with TKIs were performed
using the Wilcoxon–Mann–Whitney test for continuous variables
and w2-based tests or exact tests, as appropriate, for categorical
variables. For all results, P-values are reported for descriptive
purposes only. Statistical analysis was performed using SAS version
9.2 (SAS Institute Inc., Cary, NC, USA) with the exception of
baseline characteristics and AEs, for which version SAS version 9.4
was used.
RESULTS
Patients. Of the 113 patients enrolled between 11 March 2010 and
14 December 2010, 99 were randomised and 96 received either
nintedanib (n¼ 64) or sunitinib (n¼ 32) (Figure 1; Table 1). Three
patients in the nintedanib group were not treated and were
excluded from the safety and efficacy evaluations; reasons for
withdrawal are outlined in Figure 1. Baseline characteristics were
balanced (Table 1), and there was a male predominance in both
groups (68.8%). Most patients had a favourable/intermediate
MSKCC score (95.3% vs 93.8%), and had undergone prior
nephrectomy (87.5% in both groups). The number of metastatic
sites showed a similar pattern between the groups, but a higher
proportion of patients in the nintedanib vs the sunitinib group had
113 Patients screened
99 Patients randomised
67 Assigned to nintedanib
3 Did not receive treatmenta
64 Received treatment
(safety and efficacy
population)
4 Receiving treatment
at data cut-off
3 Receiving treatment
at data cut-off
60 Discontinued treatment
46 Progressive disease
8 Other adverse event
3 Withdrew consent
3 Otherb
29 Discontinued treatment
23 Progressive disease
4 Other adverse event
1 Non-compliant
1 Lost to follow-up
32 Received treatment
(safety and efficacy
population)
32 Assigned to sunitinib
14 Excluded owing to violation of 
inclusion or exclusion criteria
Figure 1. Patient enrolment and study flow (CONSORT diagram). aOne patient was randomised in error and had no measurable disease; one
patient withdrew consent prior to receiving their first dose of study treatment; and one patient who was admitted with pleural effusion was not
considered well enough to continue, and was withdrawn before receiving their first dose of study treatment. bOne patient discontinued treatment
with a left ventricular fraction level below threshold, one patient discontinued with signs of clinical progression that were not confirmed, and a
further one patient discontinued with evidence of increasing bone destruction of the right maxilla but no other sites of progression.
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metastases in the bone (43.8% (n/N¼ 28/64) vs 25.0% (8/32)) or
liver (34.4% (22/64) vs 25.0% (8/32)).
Treatment. As of the analysis cut-off date of 21 February 2014,
93.8% and 90.6% of patients treated with nintedanib and sunitinib,
respectively, had discontinued treatment, whereas the remaining
four (6.3%) and three (9.4%) patients in the nintedanib and
sunitinib groups, respectively, were continuing treatment. Treat-
ment discontinuation due to progressive disease occurred in 71.9%
of patients, and treatment discontinuation owing to the other AEs
occurred in 12.5% of patients, in both groups. The mean (median;
range) duration of study treatment exposure was 348 (252; 22–1303)
and 391 (239; 4–1334) days for patients in the nintedanib and
sunitinib groups, respectively. Dose reductions occurred in 25.0%
of patients in each treatment group, with a mean time to first dose
reduction of 209 days with nintedanib and 186 days with sunitinib.
Efficacy. The primary efficacy endpoint of PFS at 9 months was
43.1% for patients treated with nintedanib and 45.2% for sunitinib,
derived from KM estimates (P¼ 0.85 for the intergroup compar-
ison). Post hoc sub-analysis revealed PFS at 9 months for patients
with liver or bone metastases at baseline to be 29.0% and 43.9%,
respectively, with nintedanib and 14.3% and 25.0% with sunitinib.
Median investigator-assessed PFS in the overall treatment groups
was 8.4 months in each group (HR, 1.12; 95% CI: 0.70–1.80;
P¼ 0.64; Figure 2). Summaries of PFS for the patient subgroups
defined by stratification factors (prior nephrectomy (yes/no) and
MSKCC risk score (favourable–intermediate/poor) did not reveal
any notable differences between groups. Median PFS for patients
with liver metastases at baseline was 8.4 months with nintedanib
and 5.6 months with sunitinib (HR, 0.43; 95% CI: 0.17–1.05;
P¼ 0.06). Progression-free survival was comparable in both
treatment groups for patients with bone metastases at baseline.
In the overall treatment groups, median TTP was 8.5 months
(HR, 1.14; 95% CI: 0.70–1.87; P¼ 0.60) and median TTF was 8.4
months (HR, 1.14; 95% CI: 0.72–1.81; P¼ 0.57). At the cut-off date
for this 3-year analysis, disease progression was recorded for 49
(76.6%) and 25 (78.1%) patients in the nintedanib and sunitinib
groups, respectively, and treatment failure for 58 (90.6%) and 28
(87.5%) patients, respectively.
A confirmed OR was achieved by 20.3% and 31.3% of patients
in the nintedanib and sunitinib groups, respectively (OR, 0.58; 95%
CI: 0.22–1.51; P¼ 0.26; Table 2). The median duration of OR was
19.4 months and 12.2 months in the nintedanib and sunitinib
groups, respectively. Disease control was achieved by 76.6% and
78.1% of patients in the nintedanib and sunitinib groups,
respectively. In patients with liver metastases at baseline, a
confirmed all-disease site OR was achieved by 18.2% of patients
with nintedanib and 12.5% with sunitinib. Similarly, in patients
with bone metastases at baseline a confirmed all-disease site OR
was achieved by 21.4% with nintedanib and 12.5% with sunitinib.
At the cut-off date for the 3-year analysis, 42 (65.6%) and 21
patients (65.6%) in the nintedanib and sunitinib groups,
respectively, had died. Median OS was 20.4 and 21.2 months for
patients treated with nintedanib and sunitinib, respectively, with an
HR of 0.92 (95% CI: 0.54–1.56; P¼ 0.76; Figure 3). In the post hoc
sub-analysis of patients with liver metastases at baseline, a median
OS of 12.1 months was observed with nintedanib vs 8.2 months
with sunitinib (HR, 0.50; 95% CI: 0.20–1.26; P¼ 0.13). For patients
with bone metastases at baseline, median OS was 18.3 months with
nintedanib and 11.0 months with sunitinib (HR, 1.26; 95% CI:
0.43–3.72; P¼ 0.68). Post-study anticancer therapy was more
common in the nintedanib group (39.1% vs 25.0%; Supplementary
Table S3). The most common post-study anticancer therapy
overall was everolimus (12.5% for both groups), but a markedly
greater proportion of patients in the nintedanib vs sunitinib group
received interferon (14.1% vs 3.1%).
Safety. Overall incidence of any-grade AEs among patients treated
with nintedanib and sunitinib was 90.6% and 93.8%, respectively
(Table 3). Adverse events considered to be drug-related occurred in
75.0% of patients treated with nintedanib and 68.8% treated with
sunitinib. Adverse events that were grade X3 were reported in
43.8% and 59.4% of patients and serious AEs were reported in
31.3% and 34.4% of patients treated with nintedanib and sunitinib,
respectively.
The most common AEs of any grade reported with nintedanib
were diarrhoea, nausea and fatigue (Table 3). Adverse events
occurring markedly more frequently in patients receiving ninte-
danib vs sunitinib were diarrhoea, and increases in gamma-
Table 1. Patient demographics and baseline characteristics
for the treatment set
Variable
Nintedanib
(n¼64)
Sunitinib
(n¼32)
Median age, years (range) 62 (42–86) 58 (29–79)
Sex, n (%)
Male 44 (68.8) 22 (68.8)
Female 20 (31.3) 10 (31.3)
Median BMI, kg/m2 (range) 27.6 (21.4–52.7) 28.0 (18.3–37.1)
Country, n (%)
Hungary 2 (3.1) 0
Poland 14 (21.9) 6 (18.8)
Romania 5 (7.8) 0
Ukraine 33 (51.6) 18 (56.3)
UK 10 (15.6) 8 (25.0)
Race
Caucasian 64 (100) 32 (100)
Median time since first diagnosis,
years (range)
0.44 (0–11.8) 0.38 (0–9.1)
ECOG performance status, n (%)
0 13 (20.3) 10 (31.3)
1 51 (79.7) 22 (68.8)
MSKCC risk category, n (%)
Favourable/intermediate 61 (95.3) 30 (93.8)
Poor 3 (4.7) 2 (6.3)
Nuclear clinical grading, n (%)
Not available 20 (31.3) 8 (25.0)
I 3 (4.7) 2 (6.3)
II 10 (15.6) 7 (21.9)
III 9 (14.1) 5 (15.6)
IV 22 (34.4) 10 (31.3)
Metastatic sitesa, n (%)
0–1 10 (15.6) 5 (15.6)
2–3 41 (64.1) 21 (65.6)
43 12 (18.8) 6 (18.8)
Location of metastasesa, n (%)
Liver 22 (34.4) 8 (25.0)
Lung 45 (70.3) 22 (68.8)
Bone 28 (43.8) 8 (25.0)
Brain 0 0
Adrenal 13 (20.3) 6 (18.8)
Other 45 (70.3) 28 (87.5)
Prior nephrectomy, n (%)
No 8 (12.5) 4 (12.5)
Yes 56 (87.5) 28 (87.5)
Concomitant disease, n (%)
Cardiovascular 22 (34.4) 10 (31.3)
Hypertension 23 (35.9) 12 (37.5)
Abbreviations: BMI¼body mass index; ECOG¼Eastern Oncology Cooperative Group;
MSKCC¼Memorial Sloan-Kettering Cancer Center. There were no statistically significant
differences between the two groups at baseline on the basis of Wilcoxon–Mann–Whitney
tests for continuous variables and w2 based tests or exact tests, as appropriate, for
categorical variables.
aData missing for one patient in the nintedanib treatment group.
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glutamyltransferase (GGT), AST (any grade: 9.4% vs 0%) and
ALT(7.8% vs 0%). Adverse events reported more frequently by
patients receiving sunitinib vs nintedanib were: stomatitis, hand–
foot syndrome (HFS), dyspepsia, anaemia, hypertension, hypothyr-
oidism, dyspnoea and increased lipases.
The incidences of AEs associated with VEGF inhibitors were
comparable between the nintedanib and sunitinib groups:
thromboembolic events and haemorrhage (Table 4). Interestingly,
the rates of hypertension (10.9% vs 15.6%) and hypothyroidism
(3.1% vs 15.6%) were lower in the nintedanib arm than the
sunitinib arm. There were no recorded events of gastrointestinal
(GI) perforation in either group (Table 4).
Rates of patients with any-grade AEs associated with cardiac
disorders were comparable with nintedanib and sunitinib (Table 4).
All cardiac disorder events were grade 1 or 2, with the exception of
one patient in each group with a myocardial infarction.
The proportion of patients with AEs (of any grade) in the
nintedanib vs sunitinib groups were markedly lower for dermato-
logic AEs, such as HFS, which was not observed in nintedanib-
treated patients (Table 4). Haematological AEs occurred more
frequently in patients in the sunitinib group.
The most frequent AEs (X5%) leading to dose reduction in
either group were diarrhoea (10.9% with nintedanib vs 6.3% with
sunitinib), stomatitis (0.0% vs 9.4%), fatigue (0.0% vs 6.3%) and
lethargy (0.0% vs 6.3%). Discontinuations due to AEs occurred in
17.2% and 15.6% of patients treated with nintedanib and sunitinib,
respectively. Adverse events leading to death occurred for one
patient in the nintedanib group (myocardial infarction and
cerebrovascular accident) and one in the sunitinib group (ascites),
which were not considered by the investigator to be drug-related.
Therapy discontinuation secondary to AEs, mean duration of
treatment exposure, and dose reductions appeared similar for both
the nintedanib and sunitinib groups. This suggests patient
tolerability was similar for both drugs.
DISCUSSION
The overall efficacy of TKIs in renal cancer has been limited
because of issues with drug resistance and toxicity (Conti et al,
2013). Sunitinib has become established as a standard-of-care for
first-line treatment of metastatic RCC based on significant survival
benefits in comparison with traditional cytokine-based therapy
(Motzer et al, 2007, 2009). However, safety data from clinical trials
and a sunitinib expanded access programme have demonstrated
relatively high rates of AEs experienced by patients (Motzer et al,
2007, 2009; Gore et al, 2009). A recent observational study of
clinical practice patterns reported that 10.3% of patients with RCC
experienced a grade 3 or 4 AE over 24 weeks of first-line sunitinib
therapy (Porta et al, 2014). The most frequent grade 3/4 AEs were
fatigue, mucositis/stomatitis, diarrhoea, HFS, pain and thrombotic
events. At 24 weeks, 31.8% of patients had experienced at least one
sunitinib dose reduction, 20.3% at least one treatment interruption
and 5.5% of patients had discontinued treatment. Overall, more
than one third of patients required at least one treatment
modification due to an AE in the first 24 weeks of treatment and
there was a statistically significant inverse correlation between AEs
and dose intensity. Importantly, a significant relationship was also
observed between dose intensity and shorter survival, and between
dose discontinuation and shorter survival. These data emphasise
the importance of tolerability to efficacy outcomes for antiangio-
genic TKIs in RCC.
In the current exploratory study, treatment with nintedanib
provided an investigator-assessed 9-month PFS and median PFS
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Figure 2. Kaplan–Meier plot for progression-free survival by investigator assessment. Patients without documented progression were censored
at the date of their last tumour assessment. Crosses denote censoring events. At the cut-off date for 3-year analysis, 53 patients (82.8%) in the
nintedanib group and 27 (84.4%) in the sunitinib group had progressed or died. Hazard ratio and confidence intervals for the overall treatment
groups were obtained from Cox proportional hazards models stratified by Motzer risk score and previous surgery. Abbreviations: CI¼ confidence
interval; HR¼hazard ratio.
Table 2. Confirmed best tumour response and disease
control according to RECIST version 1.1 criteria
Variable, n (%) Nintedanib (n¼64) Sunitinib (n¼32)
Disease control 49 (76.6) 25 (78.1)
Objective response 13 (20.3) 10 (31.3)
Confirmed best tumour response
Complete response 0 (0.0) 1 (3.1)
Partial response 13 (20.3) 9 (28.1)
Stable disease 36 (56.3) 15 (46.9)
Progressive disease 14 (21.9) 5 (15.6)
Not evaluable 1 (1.6) 2 (6.3)
Abbreviation: RECIST¼Response Evaluation Criteria in Solid Tumors.
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and OS similar to sunitinib. These outcomes were greater with
nintedanib than sunitinib in a post hoc sub-analysis of patients with
liver metastases at baseline, although confirmation in a larger scale
trial is required. Nevertheless, this observation is interesting given
that the presence of metastases at these sites has a significant
negative impact on survival in patients treated with targeted agents,
including antiangiogenic agents (Mckay et al, 2014). The overall
findings of this study are consistent with a study comparing
first-line nintedanib with standard-of-care sorafenib in 95 Asian
patients with advanced HCC (Cheng et al, 2015). In that study,
efficacy was comparable between the groups, but nintedanib had a
more favourable safety profile than sorafenib, with lower rates of
AEs rated gradeX3 (56% vs 84%), serious AEs (46% vs 56%), AEs
leading to dose reductions (19% vs 59%) and drug discontinuation
(24% vs 34%; Cheng et al, 2015). A similar study of 93 European
patients with HCC also showed that efficacy with nintedanib was
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Figure 3. Kaplan–Meier plot for overall survival. Patients without documented death at the time of analysis were censored on the date that they
were last known to have been alive. Crosses denote censoring events. At the cut-off date for 3-year analysis, 42 patients (65.6%) in the nintedanib
group and 21 (65.6%) in the sunitinib group had died. Hazard ratio and confidence intervals for the overall treatment groups were obtained from
Cox proportional hazards models stratified by Motzer risk score and previous surgery. Abbreviations: CI¼ confidence interval; HR¼ hazard ratio;
NE¼ not evaluable.
Table 3. Summary of adverse eventsa reported in X10% of
patients in either treatment arm
Nintedanib (n¼64) Sunitinib (n¼32)
MedDRA preferred
term, n (%)
Any
grade GradeX3
Any
grade Grade X3
Patients with any serious
AE
20 (31.3) 16 (25.0) 11 (34.4) 8 (25.0)
Patients with any AE 58 (90.6) 31 (48.4) 30 (93.8) 19 (59.4)
Type of AE
Diarrhoea 40 (62.5) 2 (3.1) 16 (50.0) 1 (3.1)
Nausea 24 (37.5) 0 (0.0) 11 (34.4)b 1 (3.1)
Fatigue 16 (25.0) 2 (3.1) 8 (25.0) 2 (6.3)
Vomiting 10 (15.6) 0 7 (21.9) 1 (3.1)
Decreased appetite 10 (15.6) 0 6 (18.8) 0
Increased GGT 8 (12.5) 7 (10.9) 1 (3.1) 1 (3.1)
Decreased weight 8 (12.5) 1 (1.6) 2 (6.3) 0
Stomatitisc 0 0 10 (31.3) 2 (6.3)
Hand–foot syndromec 0 0 10 (31.3) 0
Dyspepsiac 2 (3.1) 0 7 (21.9) 0
Anaemia 4 (6.3) 0 5 (15.6) 2 (6.3)
Hypertensionc 2 (3.1) 0 5 (15.6) 2 (6.3)
Hypothyroidismc 2 (3.1) 0 5 (15.6) 0
Constipation 5 (7.8) 0 4 (12.5) 0
Dysgeusia 3 (4.7) 0 4 (12.5) 0
Increased lipase 2 (3.1) 2 (3.1) 4 (12.5) 3 (9.4)
Dyspnoeac 1 (1.6) 0 4 (12.5) 0
Abbreviations: AE¼ adverse event; GGT¼gamma-glutamyltransferase; MedDRA¼Medical
Dictionary for Regulatory Activities.
aClassified by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
bOne patient reported nausea, but their CTCAE grade was not recorded.
cPo0.05 for comparison of any grade AEs based on w2-tests or Suissa–Shuster exact tests as
appropriate.
Table 4. Summary of adverse events associated with TKIs
Nintedanib (n¼64) Sunitinib (n¼32)
Standardised
MedDRA Query, n (%)
Any
grade GradeX3
Any
grade Grade X3
Class effects of VEGF inhibitors
Hypertension 7 (10.9) 1 (1.6) 5 (15.6) 2 (6.3)
Haemorrhage 7 (10.9) 2 (3.1) 4 (12.5) 2 (6.3)
Thromboembolic events 4 (6.3) 3 (4.7) 1 (3.1) 1 (3.1)
GI perforation 0 0 0 0
Hypothyroidisma,b 2 (3.1) 0 5 (15.6) 0
Dermatological AEs
Cutaneous serious skin
reactions
0 0 12 (37.5) 3 (9.4)
Stomatitisb,c 0 0 10 (31.3) 2 (6.3)
Hand–foot syndromeb,c 0 0 10 (31.3) 0
Rasha,b 1 (1.6) 0 5 (15.6) 1 (3.1)
Cardiac AEs
Cardiac arrhythmia 8 (12.5) 0 6 (18.8) 0
Myocardial infarctionc 1 (1.6) 1 (1.6) 1 (3.1) 1 (3.1)
Cardiac failure 2 (3.1) 0 1 (3.1) 0
Haematological AEs
Anaemiac 4 (6.3) 0 5 (15.6) 2 (6.3)
Neutropeniab,c 0 0 3 (9.4) 0
Thrombocytopeniac 0 0 2 (6.3) 2 (6.3)
Abbreviations: AE¼ adverse event; GI¼gastrointestinal; TKI¼ tyrosine kinase inhibitor.
aTailored special search category.
bPo0.05 for comparison of any grade AEs based on Suissa–Shuster exact tests.
cMedDRA preferred term.
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comparable to sorafenib and that nintedanib was associated with a
manageable safety profile (Palmer et al, 2015).
In the current study, the most frequent any-grade AEs
associated with nintedanib vs sunitinib were diarrhoea (62.5% vs
50.0%), nausea (37.5% vs 34.4%) and fatigue (25.0% vs 25.0%);
however, the majority of these AEs were grade 1 or 2, and the
incidence of grade X3 events for nintedanib was comparable to
that for sunitinib. The rate of patients with AEs of increased GGT,
ALT and AST liver enzymes was higher with nintedanib than with
sunitinib, while AEs of increased lipases were higher with sunitinib
than for nintedanib.
Although treatment with antiangiogenic TKIs has been
associated with certain specific AEs, including, bleeding, GI
perforation and thromboembolism, nintedanib showed only
moderate frequencies of hypertension, hypothyroidism and any
cardiac AEs and there were no signs and symptoms for HFS,
stomatitis or any haematological laboratory abnormalities.
(Ravaud, 2011) Hypertension was once considered a potential
indicator for efficacy of anti-VEGF therapy but it has not been
validated as a predictive marker and a recent meta-analysis
showed no association (Hurwitz et al, 2013). Furthermore, the
frequency and severity of hypertension as an AE varies between
studies, depending on the tumour type and other patient-related
factors. Therefore, a moderate rate of hypertension with
nintedanib does not indicate a lack of VEGFR inhibition. It
should also be mentioned that the rather low incidences of these
specific AEs are unlikely to reflect inadequate dosing: the
pharmacokinetic characteristics of nintedanib in this study
population (Eisen et al, 2013), were similar to those seen with
nintedanib for other tumour types (Ellis et al, 2010; Okamoto
et al, 2010; Doebele et al, 2012; Du Bois et al, 2013).
As previously reported, treatment with nintedanib in this study
was not associated with QT prolongation (Eisen et al, 2013).
Comparing ECG traces at baseline and day 15, slight increases in
QTcF were seen at certain time points. However, the upper
limits of the two-sided 90% CIs for the adjusted mean time-
matched changes were well below the regulatory threshold of
10ms at all times (Eisen et al, 2013). Safety data presented in this
report also revealed a low rate of cardiovascular AEs in both
groups. Therefore, the safety profile of nintedanib appears to be
generally manageable by dose reductions and symptomatic
treatment.
Limitations of this study were that it was a Phase II exploratory
study not powered to detect a significant difference in efficacy
parameters. Furthermore, patients and physicians were not blinded
to the study treatment, which may have influenced outcomes, and
no quality of life parameters were included to provide insight into
the implications of differences between the treatment arms. Future
studies should also include analysis of biomarkers to investigate the
biological implications of FGFR inhibition in previously untreated
patients and in patients previously treated with anti-VEGF therapy.
As an inhibitor of VEGFR, PDGFR and FGFR angiogenic
signalling pathways, nintedanib may have the potential to overcome
acquired resistance seen with other antiangiogenic TKIs. A recent
Phase III study of the FGFR inhibitor dovitinib did not show a
significant benefit over sorafenib in patients with metastatic RCC who
had failed one prior VEGF pathway-targeted agent and one prior
mammalian target of rapamycin (mTOR) inhibitor (Motzer et al,
2014). However, the vast majority of patients (92%) entered the study
having received mTOR inhibitor therapy after VEGF-targeted
therapy, and FGF2 levels were not increased at baseline. It is
conceivable that FGF2 levels may have risen during VEGF
pathway-targeted therapy, reflecting FGFR-mediated resistance,
only to fall again during mTOR inhibitor therapy. Thus, further
study of FGFR inhibitors that includes rigorous biomarker analysis
is required to determine the true role of FGFR inhibitors in
overcoming resistance to VEGF-targeted therapy.
CONCLUSIONS
Previously reported data from this Phase II study demonstrated
that there was no prolongation of the QTcF interval with
nintedanib (Eisen et al, 2013). The results of the analysis reported
here show promising efficacy for nintedanib in comparison with
standard-of-care sunitinib as first-line treatment for patients with
advanced RCC. The data also suggest that nintedanib has a
manageable safety profile, with incidences of the AEs of
hypertension, hypothyroidism, cardiac disorders, HFS and hae-
matological abnormalities being lower than typically expected with
the use of a TKI. A larger-scale trial with greater statistical power is
required to confirm these efficacy and safety findings. Further
evaluation of nintedanib in advanced RCC may be explored,
particularly as second-line therapy after failure of TKIs, where
there is a continuing unmet clinical need for new therapies that
balance efficacy with a manageable safety profile.
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